Cat. No.: DAB-0012025
Product Information | |
---|---|
Clonality | Polyclonal |
Host Species | Rabbit |
Reactivity | Human |
Applications | WB |
Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys785 of human FNIP1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | FNIP1 |
UniProt No. | Q8TF40 |
Gene ID | 96459 |
Gene Description | FNIP1 and FNIP2 were identified as proteins interacting with tumor suppressor folliculin. FNIP1 and FNIP2 directly associate with AMPK, which indicates that they play roles in the energy and nutrient sensing pathways. Further studies show that the FLCN/FNIP2 complex functions as a GTPase-activating protein for Rag GTPase C and Rag GTPase D. The FLCN/FNIP2 complex thus promotes binding of mTORC1 to Rag heterodimers, leading to mTORC1 activation. In addition, along with FLCN, both FNIP1 and FNIP2 contribute to kidney tumor suppression. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.